Researchers who examined information from Bristol-Myers Squibb's clinical trials of its Pargluva diabetes drug recommended in the Journal of the American Medical Association the drug should undergo another trial to test it for heart safety. The researchers said the data show the drug could be linked to heart attacks, strokes and death. The FDA cited a need for such information in declining to approve the drug, despite a strong recommendation from an advisory panel. The drugmaker and Merck, the drug's co-marketer, said there are "many different and appropriate ways to analyze data."

Related Summaries